Popiel HA - Search Results

1

[Therapeutic strategies for the polyglutamine diseases].

Nagai Y, Popiel HA, Fujikake N, Toda T. Nagai Y, et al. Among authors: popiel ha. Brain Nerve. 2007 Apr;59(4):393-404. Brain Nerve. 2007. PMID: 17447526 Review. Japanese.

2

Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo.

Popiel HA, Nagai Y, Fujikake N, Toda T. Popiel HA, et al. Mol Ther. 2007 Feb;15(2):303-9. doi: 10.1038/sj.mt.6300045. Mol Ther. 2007. PMID: 17235308 Free article.

3

A toxic monomeric conformer of the polyglutamine protein.

Nagai Y, Inui T, Popiel HA, Fujikake N, Hasegawa K, Urade Y, Goto Y, Naiki H, Toda T. Nagai Y, et al. Among authors: popiel ha. Nat Struct Mol Biol. 2007 Apr;14(4):332-40. doi: 10.1038/nsmb1215. Epub 2007 Mar 18. Nat Struct Mol Biol. 2007. PMID: 17369839

4

Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy.

Takahashi Y, Okamoto Y, Popiel HA, Fujikake N, Toda T, Kinjo M, Nagai Y. Takahashi Y, et al. Among authors: popiel ha. J Biol Chem. 2007 Aug 17;282(33):24039-48. doi: 10.1074/jbc.M704789200. Epub 2007 Jun 15. J Biol Chem. 2007. PMID: 17573338 Free article.

5

Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice.

Popiel HA, Nagai Y, Fujikake N, Toda T. Popiel HA, et al. Neurosci Lett. 2009 Jan 9;449(2):87-92. doi: 10.1016/j.neulet.2008.06.015. Epub 2008 Jun 10. Neurosci Lett. 2009. PMID: 18603372

6

Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones.

Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, Toda T. Fujikake N, et al. Among authors: popiel ha. J Biol Chem. 2008 Sep 19;283(38):26188-97. doi: 10.1074/jbc.M710521200. Epub 2008 Jul 16. J Biol Chem. 2008. PMID: 18632670 Free PMC article.

7

Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.

Nagai Y, Popiel HA. Nagai Y, et al. Among authors: popiel ha. Curr Pharm Des. 2008;14(30):3267-79. doi: 10.2174/138161208786404164. Curr Pharm Des. 2008. PMID: 19075705 Review.

8

Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.

Nagai Y, Fujikake N, Popiel HA, Wada K. Nagai Y, et al. Among authors: popiel ha. Curr Pharm Biotechnol. 2010 Feb;11(2):188-97. doi: 10.2174/138920110790909650. Curr Pharm Biotechnol. 2010. PMID: 20166962 Review.

9

Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila.

Nagai Y, Fujikake N, Ohno K, Higashiyama H, Popiel HA, Rahadian J, Yamaguchi M, Strittmatter WJ, Burke JR, Toda T. Nagai Y, et al. Among authors: popiel ha. Hum Mol Genet. 2003 Jun 1;12(11):1253-9. doi: 10.1093/hmg/ddg144. Hum Mol Genet. 2003. PMID: 12761040

10

Disruption of the toxic conformation of the expanded polyglutamine stretch leads to suppression of aggregate formation and cytotoxicity.

Popiel HA, Nagai Y, Onodera O, Inui T, Fujikake N, Urade Y, Strittmatter WJ, Burke JR, Ichikawa A, Toda T. Popiel HA, et al. Biochem Biophys Res Commun. 2004 May 14;317(4):1200-6. doi: 10.1016/j.bbrc.2004.03.161. Biochem Biophys Res Commun. 2004. PMID: 15094397

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters